Lenvatinib or regorafenib for liver cancer after immunotherapy
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests two oral targeted therapy drugs, lenvatinib and regorafenib, in people with advanced liver cancer (hepatocellular carcinoma) that has progressed after first-line immunotherapy-based treatment. The goal is to see if these drugs can control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 19 or older.
- You have a type of liver cancer called hepatocellular carcinoma (HCC).
- Your liver cancer cannot be removed with surgery, or it has spread to other parts of the body.
- You have already had one line of systemic treatment that included an immunotherapy-based combination (such as atezolizumab plus bevacizumab, durvalumab plus tremelimumab, or similar).
- Your cancer grew or worsened after at least 2 cycles of that first treatment.
- You have a liver function score of Child-Pugh A or B, depending on the study group.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy pill (regorafenib) for people with advanced liver cancer that has progressed after first-line treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests regorafenib, a targeted therapy, for people with advanced liver cancer that progressed after first-line immunotherapy. It aims to slow tumor growth and may offer a new option when standard treatment stops working.
This trial tests a new drug, regorafenib, for people with liver cancer that cannot be removed by surgery and who have already tried lenvatinib. The goal is to see if regorafenib can help control the cancer after lenvatinib stops working or causes too many side effects.
This trial tests whether combining two medicines (trastuzumab and regorafenib) works better than regorafenib alone for people with advanced liver cancer that has progressed after first-line treatment. It aims to see if the combination helps control the cancer longer.
This trial tests a combination of two drugs, cadonilimab and regorafenib, for people with liver cancer that has worsened after treatment with camrelizumab and apatinib. The goal is to see if this new combination can help control the cancer.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.